The CLIA certified laboratory is promising even faster turnaround times and cost savings, which they intend to pass on to their customers. Nebula has completed the buildout of its state-of-the-art genomics laboratory at its Garden City, New York headquarters outfitted with industry leading next generation sequencing (NGS) equipment to perform WGS and an array of genetic diagnostic test offerings, for both clinical and research applications. Nebula also provides consumers with weekly educational content to further their knowledge about the use of their genetic data. Through the use of additional tools, the data that is generated can identify rare genetic mutations, and is diagnostics-ready, providing valuable information to healthcare providers in a HIPPA-compliant format and providing consumers insights into their health and wellness. Nebula’s WGS DNA test decodes ~6.4 billion base pairs of the human genome, generating significant amounts of data, which exceeds the amount and quality of data widely offered by most competing services. Church has pioneered the development of multiple DNA sequencing methods, including molecular multiplexing approaches that enable next generation sequencing (NGS) as well as nanopore sequencing. Nebula’s solution is powered by the innovations of George Church, Ph.D., Professor of Genetics at Harvard Medical School and Chairman of Nebula’s Scientific Advisory Board. “We feel strongly that Nebula’s powerful combination of reports and exploration tools position us to transcend the personal DNA space.” “We take pride in our ability to produce timely and relevant reports” continued Mr. These tools allow customers to browse their data, search for genetic variants, and analyze their genes. In addition to the personalized reports, Nebula provides customers with access to a suite of exploration tools including a gene browser and a gene analysis tool. As new scientific discoveries are made, customers receive new reports, as well as regular updates to their existing reports, through Nebula’s subscription model. Customers can access their reports via Nebula’s secure online portal. These reports are created utilizing the latest scientific research and provide individual genetic predispositions for a broad range of traits and characteristics. Nebula also provides customers with access to over 300 personalized reports based on their genomic profile. Nebula provides consumers access to affordable and secure whole genome sequencing. We seek to harness the power of the entire human genome, while delivering as much value as possible to our customers.” “It’s our view that the future of health and wellness is personalized therapies based on each individual’s genetic makeup, and our WGS services, now more accessible than ever, enables that future. “Our mission at Nebula is to usher in a new era of personal genomics by providing access to affordable and secure whole genome sequencing, and today’s announcement marks strong progress toward this goal,” continued Mr. “With limited competing products that offer standard pricing between $400-$1100, Nebula Genomics’ new standard price is the most affordable in the United States for 30X WGS and further cements us as a leader in DTC WGS services,” commented Ted Karkus, ProPhase Labs’ Chief Executive Officer. (“Nebula”), has introduced its lowest ever standard price of $249.00 for its direct-to-consumer (DTC) whole genome sequencing (WGS) DNA test. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its wholly owned subsidiary, Nebula Genomics, Inc. Garden City, NY, Ma(GLOBE NEWSWIRE) - ProPhase Labs, Inc. Company Provides Update on Significant Progress at Nebula Genomics Subsidiary
0 Comments
Leave a Reply. |